Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis (MASH) for $4.7 billion upfront, shortly after claiming FDA approval to ...
Metabolic dysfunction-associated steatohepatitis (MASH), previously called nonalcoholic steatohepatitis (NASH), is a more severe form of fatty liver disease that causes inflammation and damage. MASH ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results